Study of XL999 in Patients With Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This clinical study is being conducted at multiple sites to determine the activity, safety,
and tolerability of XL999 when given weekly to patients with non-small cell lung cancer
(NSCLC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR,
FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels
(angiogenesis), and metastasis.